Clinical Course of Hypertrophic Cardiomyopathy in a Regional United States Cohort

Abstract
Hypertrophic cardiomyopathy (HCM) is a complex familial cardiac disease with heterogeneous clinical, morphologic, and genetic expression.1-4 Since its initial description 40 years ago, HCM has been largely regarded to be associated with substantial disability and premature death, and annual mortality rates as high as 3% to 6% have been reported.1,3,5-14